文献速递其他结缔组织病

并发炎性肌病与重症肌无力伴或不伴胸腺病变:病例系列与文献综述

Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: A case series and literature review.
PubMed 文献 · Semin Arthritis Rheum · 2018-06-28

该病例系列报告了2004至2017年间在加拿大温哥华一家三级转诊中心神经肌肉疾病项目随访的7例并发重症肌无力(MG)与炎性肌病(IM)患者,并复习文献比较既往报告病例。7例患者均以眼肌或延髓受累为MG表现,4例存在胸腺病变且均有乙酰胆碱受体(AChR)抗体,多数对糖皮质激素、乙酰胆碱酯酶抑制剂和免疫抑制剂反应良好,2例无胸腺瘤的难治性患者对利妥昔单抗有反应。

要点

  • 7例MG与IM并发患者中,MG均表现为眼肌或延髓受累,4例有胸腺病变且均AChR抗体阳性。
  • 3例MG与IM同时起病,其中2例以肌无力危象和暴发性肌炎起病;另4例MG起病后3至11年出现IM。
  • 2例无胸腺瘤的难治性MG与IM患者对利妥昔单抗有反应,此前未见该病此种治疗的报告。

核心结论

  • 这是伴或不伴胸腺病变的MG-IM重叠病例系列中规模最大的系列之一。
  • 在该队列中,两种疾病可同时发生,也可一种先于另一种出现。
  • 多数患者对糖皮质激素、乙酰胆碱酯酶抑制剂和免疫抑制剂反应良好。
  • 在非常难治的病例中,利妥昔单抗似乎有效,此前未见该病此种治疗的报告。

研究设计与样本

  • 研究识别了2004至2017年间在加拿大不列颠哥伦比亚省温哥华一家三级转诊中心神经肌肉疾病项目随访的7例并发MG与IM患者,并进行文献复习,将既往报告病例与本系列患者进行比较。

主要发现

  • 全部7例患者均以眼肌或延髓受累为MG表现。
  • 3例患者MG与IM同时起病,其中2例表现为肌无力危象和暴发性肌炎。
  • 另4例患者中MG为首发表现,IM在MG后3至11年发生。
  • 7例患者中4例存在基础胸腺病变,包括2例良性胸腺瘤和2例IV期胸腺瘤,全部4例均有乙酰胆碱受体(AChR)抗体。
  • 3例经影像学或组织学无胸腺病变的患者中,2例AChR抗体滴度阳性。

关键数值与推荐

  • 胸腺瘤被切除,并酌情给予化疗。
  • 为达到缓解,需要使用包括大剂量糖皮质激素、静脉注射免疫球蛋白(IVIG)、甲氨蝶呤、吗替麦考酚酯或环孢素在内的额外免疫抑制治疗。
  • 2例无胸腺瘤患者存在难治性MG和IM,均对利妥昔单抗有反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The association of myasthenia gravis (MG) and inflammatory myositis (IM) is rare and typically only one of the diseases is present. The management of the 2 diseases differs, therefore it is important to recognize the concomitant presentation. Here, we report a case series of 7 patients with co-existing MG and IM with review of the literature. METHOD: We identified 7 patients with concurrent MG and IM who were followed at the Neuromuscular Disease Program at a tertiary referral center in Vancouver, British Columbia from 2004 to 2017. RESULT: All 7 patients had ocular or bulbar involvement as manifestation of MG. Three patients had simultaneous onset of MG and IM, 2 of whom presented with myasthenia crisis and fulminant myositis. In the other 4 patients, MG was the initial presentation and IM occurred 3-11 years after MG. Among these 7 patients, 4 had underlying thymic pathology, including 2 with benign thymoma and 2 with stage IV thymoma; all 4 patients had antibodies to acetylcholine receptor (AChR). Of the 3 patients with no thymic pathology by imaging or histology, 2 had positive AChR antibody titer. For treatment, the thymoma was resected and chemotherapy was administered if appropriate. Additional immunosuppressive therapies including high-dose glucocorticoid, intravenous immunoglobulin (IVIG), methotrexate, mycophenolate, or cyclosporine were necessary to achieve remission. Two patients with no thymoma had refractory MG and IM, and both responded to rituximab. We also conducted a literature review on the clinical characteristics and management of this condition, and compared the previously reported cases to the patients in our series. CONCLUSION: This is one of the largest case series of MG-IM overlap with or without thymic pathology. In this cohort, the 2 disease entities can occur simultaneously, or one presents before the other. Most of the patients responded well to steroid, acetylcholinesterase inhibitor, and immunosuppressive agents. In very refractory cases, rituximab appeared to be effective, which has not been reported for the treatment of this condition before.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Huang K, Shojania K, Chapman K, et al. Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: A case series and literature review. Semin Arthritis Rheum. 2018. PMID: 29958689. doi:10.1016/j.semarthrit.2018.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。